Shibo V Jiang

US Patent:

6596497, Jul 22, 2003

Filed:

Mar 14, 2000

Appl. No.:

09/525874

Inventors:

Shibo Jiang - Jackson Heights NY
Asim K. Debnath - Fort Lee NJ

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

G01N 3353

US Classification:

435 71, 4241601, 435 4, 435 5, 435 772, 435 792, 435 793, 435 794, 436501, 5303881, 5303883, 5303891, 5303894

Abstract:

A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody. A method for inhibiting HIV-1 virus replication or infectivity in a patient by administering to the patient an antiviral compound targeted to the HIV-1 gp41 core structure selected from the group consisting of 7-[6-phenylamino-4[4-[(3,5-disulfo-8-hydroxynaphthyl)azo]-2-methoxy-5-methyl-phenylamino]-1,3,5-triazine-2-yl]-4-hydroxy-3-[(2-methoxy-5-sulfophenyl)azo]-2-naphthalene sulfonic acid and 5-[(4-chloro-6-phenylamino-1,3,5-triazine-2-yl)-amino]-4-hydroxy-3-[(4-methyl-5-sulfophenyl)azo]-2,7-naphthalene disulfonic acid.

US Patent:

6727240, Apr 27, 2004

Filed:

Oct 21, 1994

Appl. No.:

08/342745

Inventors:

Alexander R. Neurath - New York NY
Shibo Jiang - New York NY
Asim Kumar Debnath - New York NY

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

A61K 31555

US Classification:

514185

Abstract:

A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.

US Patent:

7241803, Jul 10, 2007

Filed:

Nov 12, 2003

Appl. No.:

10/706027

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Asim Kumar Debnath - Fort Lee NJ, US

Assignee:

New York Blood Center - New York NY

International Classification:

C07D 207/327
A61K 31/402

US Classification:

514427, 548560, 548563

Abstract:

A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with ICvalues

US Patent:

7629443, Dec 8, 2009

Filed:

Feb 8, 2006

Appl. No.:

11/351108

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Yuxian He - Bronx NY, US

Assignee:

New York Blood Center, Inc. - New York NY

International Classification:

C12P 21/08

US Classification:

5303883

Abstract:

The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.

US Patent:

7919101, Apr 5, 2011

Filed:

Aug 12, 2009

Appl. No.:

12/540325

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Chungen Pan - Guangzhou, CN

Assignee:

New York Blood Center - New York NY

International Classification:

A61K 39/21

US Classification:

4241881, 4242081

Abstract:

Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.

US Patent:

8309602, Nov 13, 2012

Filed:

Oct 7, 2008

Appl. No.:

12/682513

Inventors:

Lan Xie - Beijing, CN
Bingjie Qin - Beijing, CN
Kuo-Hsiung Lee - Chapel Hill NC, US
Shibo Jiang - Fresh Meadows NY, US
Hong Lu - Bayside NY, US

Assignee:

Institute of Pharmacology and Toxicology - Beijing
Academy of Military Medical Sciences P.L.A. China - Beijing

International Classification:

A61K 31/277
A61K 31/136
C07C 255/50
C07C 255/51
C07C 211/46

US Classification:

514524, 514525, 514658, 558418, 558420, 564441

Abstract:

The present invention relates to multi-substituted m-diarylanilines or pharmaceutically acceptable salts thereof, wherein X, R-Rare as defined in the claims, their preparation process, pharmaceutical compositions comprising them and their use for the manufacture of a medicament for anti-HIV.

US Patent:

20060287319, Dec 21, 2006

Filed:

Jun 6, 2006

Appl. No.:

11/448439

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Asim Debnath - Fort Lee NJ, US
Hong Lu - Bayside NY, US

International Classification:

A61K 31/53
A61K 31/501
A61K 31/497
A61K 31/496
A61K 31/4439
A61K 31/427

US Classification:

514241000, 514252130, 514255050, 514252020, 514252050, 514369000, 514253090, 514341000, 514342000

Abstract:

A group of compounds that inhibit HIV replication by blocking HIV entry was identified. One representative compound, designated NB-206, and its analogs inhibited HIV replication (p24 production) with ICvalues at nanomolar levels. It was proved that NB-206 and its analogs are HIV entry inhibitors by targeting the HIV gp41 since: 1) they inhibited HIV-mediated cell fusion; 2) they inhibited HIV replication only when they were added to the cells less than one hour after virus addition; 3) they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation-specific MAb NC-1; and 4) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE). These results suggested that NB-206 and its analogs may interact with the hydrophobic cavity and block the formation of the fusion-active gp41 coiled coil domain, resulting in inhibition of HIV-1 mediated membrane fusion and virus entry.

US Patent:

20070232684, Oct 4, 2007

Filed:

May 24, 2007

Appl. No.:

11/753244

Inventors:

Shibo Jiang - Fresh Meadows NY, US
Asim Debnath - Fort Lee NJ, US

International Classification:

C07D 207/30
A61K 31/00
A61K 31/40

US Classification:

514429000, 514001000, 548563000

Abstract:

A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with ICvalues